JIANMIN GROUP(SH:600976)2021-10-21 16:00Financial Performance - The company's revenue for Q3 2021 reached ¥813,301,731.81, representing a year-on-year increase of 40.45%[6] - Net profit attributable to shareholders for Q3 2021 was ¥89,948,341.06, up 31.10% compared to the same period last year[6] - The net profit for the first nine months of 2021 increased by 104.36% year-on-year, driven by the sales growth of key products such as Longmu Bone Strengthening Granules[9] - Basic earnings per share for Q3 2021 were ¥0.59, reflecting a 30.78% increase year-on-year[8] - Net profit for the third quarter of 2021 was ¥257,844,521.81, up from ¥126,379,141.72 in the same quarter of 2020, reflecting a growth of approximately 103.5%[30] - The total comprehensive income for the third quarter of 2021 was CNY 257,844,521.81, compared to CNY 126,379,141.72 in the same period of 2020, representing a significant increase[31] - The company’s total comprehensive income attributable to the parent company for the third quarter of 2021 was CNY 257,101,116.94, compared to CNY 125,808,429.31 in the same period of 2020, reflecting a growth of 104.5%[31] Cash Flow and Assets - The operating cash flow for the first nine months of 2021 saw a significant increase of 193.84% year-on-year, attributed to improved collection management and increased sales receipts[9] - Cash inflow from operating activities for the first nine months of 2021 was CNY 2,588,679,046.80, compared to CNY 1,590,421,916.28 in the same period of 2020, reflecting an increase of 62.8%[34] - The net cash flow from operating activities for the first nine months of 2021 was CNY 192,572,225.32, compared to CNY 65,537,390.81 in the previous year, showing a growth of 194.5%[34] - Cash and cash equivalents at the end of the third quarter of 2021 totaled CNY 255,488,995.43, up from CNY 101,394,870.28 at the end of the same period in 2020, representing an increase of 151.1%[35] - Total assets at the end of Q3 2021 amounted to ¥2,677,610,352.53, a 10.77% increase from the end of the previous year[8] - The total assets as of the third quarter of 2021 amounted to ¥2,677,610,352.53, compared to ¥2,417,176,831.31 in the previous year, marking an increase of about 10.7%[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,082[16] - The largest shareholder, Huali Pharmaceutical Group Co., Ltd., holds 37,014,073 shares, accounting for 24.13% of total shares[16] - The company reported a total equity attributable to shareholders of ¥1,486,227,513.99 at the end of Q3 2021, a 12.86% increase from the previous year[8] - The company's total equity reached ¥1,493,324,595.33 in the third quarter of 2021, compared to ¥1,323,261,471.50 in the previous year, indicating an increase of about 12.9%[26] Expenses and Liabilities - Total operating costs for the third quarter of 2021 were ¥2,435,006,561.46, compared to ¥1,561,388,126.38 in the previous year, indicating an increase of about 55.8%[28] - Total liabilities for the third quarter of 2021 were ¥1,184,285,757.20, an increase from ¥1,093,915,359.81 in the same period of 2020, representing a growth of approximately 8.3%[26] - Research and development expenses for the third quarter of 2021 were ¥25,621,608.79, slightly up from ¥24,521,743.39 in the same period of 2020, showing a growth of approximately 4.5%[28] Inventory and Receivables - The company reported accounts receivable of RMB 543,293,381.61, significantly up from RMB 161,912,097.21 in the previous year[22] - Inventory decreased to RMB 123,496,590.88 from RMB 228,998,205.16 year-over-year[22] Share Repurchase and Incentives - The company plans to repurchase shares with a total fund of no less than RMB 25 million and no more than RMB 40 million, having already repurchased 1,432,001 shares[19] - The total number of shares repurchased represents 0.93% of the company's total share capital[19] - The company has granted a total of 1,062,401 restricted stocks to 7 eligible incentive objects as part of its 2021 restricted stock incentive plan[19]